tablets "Vendiol" are applied to hormonal oral contraception. Making the decision on prescribing of the medicine "Vendiol", it is necessary to consider the current risk factors for the certain woman, especially risk factors of a venous thrombembolia (VTE), and that, the risk of VTE at use of Vendiol medicine in comparison with other combined hormonal contraceptives is how high.

Structure

Active ingredients: gestoden, ethinylestradiol.

:

• active ingredients: 0.060 mg of the gestoden (micronized) and 0.015 mg of the ethinylestradiol (micronized);
• excipients: lactoses monohydrate, cellulose microcrystalline (type 112), potassium polakrilin, magnesium stearate;
• film cover: opadray ІІ yellow 31K32378, lactoses monohydrate, gipromelloza (type 2910), titan dioxide (E 171), triacetin, dye quinolinic yellow (E 104).

:

• active ingredients: are absent;
• excipients: cellulose microcrystalline, lactose waterless, starch corn prezhelatinizirovanny, magnesium stearate, silicon dioxide colloidal waterless;
• film cover: opadray ІІ green 85F21389, polyvinyl alcohol, titan dioxide (E 171), macrogoal 3350, talc, dye indigo carmine (E 132), dye quinolinic yellow (E 104), dye ferrous oxide black (E 172), dye yellow decline (E 110).

Contraindication

Combined Hormonal Contraceptives (CHC) should not be applied in the following cases. At emergence of any of these states at application the CPC should stop its reception immediately.

Hypersensitivity to active ingredients or to any of excipients.

Existence or risk of a venous thrombembolia (VTE):

• venous thrombembolia - is available VTE (use of anticoagulants) or VTE in the anamnesis (for example, the deep vein thrombosis (DVT) or a pulmonary embolism (TELA)); the known hereditary or acquired tendency to a venous thrombembolia, for example, resistance to the activated protein With (the FPÖ, including the V Leiden factor), insufficiency of antithrombin-III, insufficiency of a protein of C, insufficiency of a protein of S;
• considerable surgical intervention with a long immobilization;
• high risk of a venous thrombembolia, owing to existence of multiple factors of risk.

Existence or risk of an arterial thrombembolia (ATE):

• arterial thrombembolia - is available an arterial thrombembolia, an arterial thrombembolia in the anamnesis (for example, a myocardial infarction) or a prodromal state (for example, stenocardia);
• cerebrovascular disease - is available a stroke, a stroke in the anamnesis, a prodromal state (for example, the tranzitorny ischemic attack (TIA));
hereditary or acquired tendency to an arterial thrombembolia, for example, a gipergomotsisteinemiya and anti-phospholipidic antibodies (anti-cardiolipin antibodies, lupoid anticoagulant) is known to
• ;
• migraine with focal neurologic symptoms in the anamnesis;
• high risk of an arterial thrombembolia as a result of multiple factors of risk or existence of any of the following serious risk factors:
  • diabetes with vascular complications;
  • heavy arterial hypertension;
  • heavy dislipidemiya;
  • existence of a malignant new growth of mammary glands or suspicion on it;
  • a carcinoma of endometrium or presence of any other estrogenzavisimy tumor or suspicion on it; presence of tumors of a liver (benign or malignant) or such tumors in the anamnesis, a serious illness of a liver (so far function of a liver will not be restored);
  • heavy renal failure or sharp renal failure;
  • bleeding from a vagina of not clear etiology;
  • presence of pancreatitis or pancreatitis in the anamnesis if it is connected with a heavy gipertriglitseridemiya.

Route of administration

For oral administration.

Tablet entirely, without chewing, if necessary, washing down with a small amount of liquid daily approximately at the same time in the order specified on the blister packing. It is necessary to take one pill a day (it is desirable at the same time day) within 28 days in a row (on one yellow tablet a day within 24 days, then on one green tablet of placebo a day the next 4 days) without interruption between acceptance of tablets from the following packing. Cancellation bleeding usually begins in 2-3 days after reception of the last tablet containing active agent and can proceed prior to reception of tablets from new packing.

gave a fact-finding part of the instruction, read the full instruction in packing.

Pregnant

Vendiol is contraindicated to

Feature of application

during chest feeding as estrogen and progestogen get into breast milk that can negatively influence the child.

by

for application for children.

Drivers

Vendiol does not influence or has insignificant impact on ability of control of vehicles and mechanisms.

No serious side effects as a result of reception of high doses of the CPC were observed by

. The general experience of use of the PDA demonstrates that such cases can be followed by the following symptoms: nausea, vomiting, and young girls have insignificant vaginal bleedings.

specific antidote therefore treatment has to be exclusively symptomatic does not exist.

Side effects

Use of any PDA increases risk of VTE. In clinical trials the amenorrhea was found in 15% of patients. The headache, migraine, bleedings and the smearing bloody discharges were the most frequent side effects about which patients in the III phase of clinical trials and in the post-marketing period reported.

gave a fact-finding part of the instruction, read the full instruction in packing.

to Store

in original packing for protection against influence of light and moisture at a temperature not above 30 °C, out of children's reach.

Expiration date - 2 years.